Form 4: MAIA Director Chaouki Granted Stock Options

MAIA Biotechnology Director Steven M. Chaouki received a grant of 20,946 stock options exercisable at $1.80 per share.

Summary

• Steven M. Chaouki, a Director of MAIA Biotechnology, Inc. (MAIA), was granted 20,946 stock options.
• The transaction date for the option grant was October 2, 2025.
• Each option allows the holder to purchase one share of common stock at an exercise price of $1.80.
• The options were granted under MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• These options vest 100% on the date of grant and are immediately exercisable.
• The expiration date for these stock options is October 2, 2035.
• Following this transaction, Steven M. Chaouki beneficially owns 20,946 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive. The grant of options to a director is a standard incentive mechanism, aligning interests with shareholders. It's not a major event but indicates ongoing governance and compensation practices.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• Options vest 100% on the grant date, providing immediate exercisability and flexibility for the director.

Risks

• The value of the stock options is dependent on the future market price of MAIA Biotechnology's common stock exceeding the $1.80 exercise price.
• If the company's stock price does not appreciate above the exercise price, the options may expire worthless.

Future Outlook

The grant of stock options to a director under an existing equity incentive plan suggests a continued focus on long-term executive incentives and alignment with shareholder value creation, though no specific forward-looking financial guidance is provided in this filing.

Industry Context

This transaction is a routine insider compensation event common across publicly traded companies, particularly in the biotechnology sector, where equity incentives are frequently used to attract and retain talent and align management interests with long-term company performance.

Comparison to Industry Standards

• The use of stock options as a component of director compensation is a standard practice in the biotechnology industry, comparable to companies like Moderna (MRNA) or BioNTech (BNTX) which also utilize equity-based incentives for their leadership.
• The immediate vesting of options on the grant date is less common than phased vesting schedules but can be seen in certain incentive structures, particularly for non-employee directors, to provide immediate alignment without long-term service requirements.

Corporate Governance

Related Party Transactions

• The grant of stock options to Steven M. Chaouki, a director of MAIA Biotechnology, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant aims to align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making for long-term growth.
• Management: Provides an incentive for the director to contribute to the company's success, as the value of the options is tied to stock performance.

Next Steps

• Steven M. Chaouki may choose to exercise these options at any time between the grant date and the expiration date, provided the stock price is favorable.
• The company will continue to report any further changes in beneficial ownership for its insiders via Form 4 filings.

Key Dates

Keywords

MAIA Biotechnology, MAIA, Stock Options, Director Compensation, Equity Incentive Plan, SEC Form 4, Insider Transaction, Beneficial Ownership